The temporary Medicare GLP-1 Bridge program offers eligible beneficiaries certain weight-loss drugs for $50 a month. But people with diagnoses such as Type 2 diabetes or moderate-to-severe sleep apnea must seek coverage through their regular Part D plans instead.
Medicare’s new GLP-1 Bridge program is giving some beneficiaries access to certain weight-loss medications for a $50 monthly copayment. The nationwide temporary program, which began July 1, offers a new route to coverage for people using the drugs for weight management.
But the program’s eligibility rules create an important exception: people with some serious health conditions are not eligible for the Bridge benefit, even if they otherwise meet its weight-related criteria. Medicare directs beneficiaries with Type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease to their regular Part D drug plans, which may cover GLP-1 medicines for those diagnoses but can leave patients facing substantially higher out-of-pocket costs.
The distinction has drawn attention because it can leave patients with obesity and related illnesses outside the $50 program. NPR, in reporting distributed from KFF Health News, highlighted the case of a New Jersey man whose severe obstructive sleep apnea made him ineligible for Bridge despite a BMI of 42 and a history of heart-bypass surgery.
To qualify for Bridge, a person must have Medicare Part D coverage and meet clinical requirements at the start of GLP-1 treatment: a BMI of at least 35; a BMI of at least 30 plus diastolic heart failure, uncontrolled high blood pressure or chronic kidney disease at stage 3a or higher; or a BMI of at least 27 plus prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. A clinician must prescribe a covered drug and complete prior authorization when required.
The program covers Wegovy injections and tablets, Foundayo tablets, and Zepbound in its KwikPen form. It runs through December 31, 2027. The $50 payment does not count toward a beneficiary’s Part D deductible or annual out-of-pocket limit because the benefit operates separately from normal Part D coverage.
For many beneficiaries, the program is the first opportunity to obtain Medicare help paying for GLP-1 drugs prescribed solely for obesity. But its temporary status leaves longer-term coverage unresolved. CMS Administrator Mehmet Oz told reporters that the agency plans to track participation and outcomes as it considers future options, while Congress would need to act to authorize permanent Medicare coverage of weight-loss drugs.
